Sermonix Shares Two Recently Presented Posters Evaluating ESR1 Mutations in Circulating Tumor DNA From Patients With ER+/HER2- Metastatic Breast Cancer Who Were Treated With Lasofoxifene
19 déc. 2022 09h00 HE
|
Sermonix Pharmaceuticals Inc.
Posters were presented Dec. 9 at the San Antonio Breast Cancer Symposium (SABCS)One abstract addressed patients who participated in the randomized Phase 2 ELAINE 1 study that assessed investigational...
Sermonix Shares Two Posters at SABCS 2022 on ER+/HER2- Metastatic Breast Cancer Patient Survey About Knowledge of NGS and ESR1 Mutations, Quality of Life Concerns
09 déc. 2022 08h00 HE
|
Sermonix Pharmaceuticals Inc.
SAN ANTONIO, Dec. 09, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative targeted therapeutics to specifically treat...
Sermonix Pharmaceuticals Announces Poster Presentation on Phase 1 Ethnobridging Study of Lasofoxifene at the 12th AACR-JCA Joint Conference: Breakthroughs in Cancer Research — Translating Knowledge Into Practice
08 déc. 2022 12h00 HE
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated...
Sermonix Pharmaceuticals Announces Four Abstracts Accepted for Presentation at 2022 San Antonio Breast Cancer Symposium
17 nov. 2022 09h00 HE
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative targeted therapeutics to specifically treat...
Sermonix Pharmaceuticals Shares Additional Findings From Its ELAINE 1 Clinical Study at the 4th Annual Congress of the International Society of Liquid Biopsy
21 oct. 2022 10h00 HE
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated...
Sermonix Pharmaceuticals Shares Details of First-Ever Known Durable Complete Clinical Response in a Metastatic ER+/HER2- Breast Cancer Patient With an ESR1 Mutation After Prior CDK4/6 Inhibitor Treatment Via Single-Agent Hormonally Based Regimen
14 sept. 2022 11h22 HE
|
Sermonix Pharmaceuticals Inc.
Presentation delivered at the ninth-annual Metastatic Breast Cancer Research Conference in Park City, Utah Case was reported during Phase 2 study investigating efficacy of lasofoxifene, Sermonix’s...
Sermonix Pharmaceuticals Announces Results of Phase 2 Study of Lasofoxifene vs. Fulvestrant in Postmenopausal Women With Locally Advanced or Metastatic ER+/HER2- Breast Cancer and an ESR1 Mutation
13 sept. 2022 09h00 HE
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated...
Sermonix Pharmaceuticals Announces Top-Line Data From ELAINE 1 Phase 2 Study of Lasofoxifene Versus Fulvestrant Is Accepted for a Late-Breaking Oral Presentation at ESMO Congress 2022
25 août 2022 09h00 HE
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated...
Sermonix to Host Virtual Clinical Update on its ELAINE Phase 2 Clinical Programs
09 juin 2022 09h38 HE
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, June 09, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated...
Sermonix Pharmaceuticals’ Phase 2 Lasofoxifene Trial Poster Receives a GRASP Advocate Choice Award, Selected for Post-ASCO Patient Advocate Investigator Discussions
08 juin 2022 10h00 HE
|
Sermonix Pharmaceuticals Inc.
Guiding Researchers and Advocates to Scientific Partnerships (GRASP) launched in 2019 to unite patient advocates, physicians and researchers through meaningful discussions of cancer-related...